Hazard rates for mRNA levels of RRM2 in AML patients treated with Ara-C
mRNA . | GSE14468 cohort . | TCGA cohort . | ||
---|---|---|---|---|
Overall survival* . | Overall survival† . | Overall survival* . | Overall survival† . | |
RRM2 | 0.68 (0.49-0.94; .02) | 0.72 (0.51-1.01; .05) | 0.70 (0.43-1.15; .16) | 0.81 (0.49-1.33; .40) |
mRNA . | GSE14468 cohort . | TCGA cohort . | ||
---|---|---|---|---|
Overall survival* . | Overall survival† . | Overall survival* . | Overall survival† . | |
RRM2 | 0.68 (0.49-0.94; .02) | 0.72 (0.51-1.01; .05) | 0.70 (0.43-1.15; .16) | 0.81 (0.49-1.33; .40) |